Charles River Laboratories International's (CRL) mid-term sales growth has structurally slowed down, a view that is supported by recent results and outlook, peer read-across, pricing trends and updated market analysis, UBS Securities said in a note Friday.
The brokerage said it sees various pressures to the mid-term sales growth in the company's discovery and safety assessment segment, which comprises about 60% of its sales.
Among these pressures are budget pressures at big pharma and underappreciated pricing pressures, UBS said.
"We remain constructive on Charles River's positioning as a key enabler to biopharma, and its opportunity to execute on cost reductions," UBS said.
UBS downgraded Charles River to neutral from buy and cut its price target to $185 from $250.
Price: 165.17, Change: -0.63, Percent Change: -0.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.